Medtronic completes acquisition of intersect ent

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ent portfolio dublin and menlo park, calif. , may 13, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced that it has completed the acquisition of intersect ent, expanding the company's comprehensive ear, nose, and throat (ent) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.
MDT Ratings Summary
MDT Quant Ranking